Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current
1Department of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, USA;.
Summary
Maintenance therapy for diffuse large B-cell lymphoma (DLBCL) shows promise with lenalidomide, particularly for higher-risk patients. Further research is needed to identify optimal patient selection for this approach.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Maintenance therapy is established in indolent non-Hodgkin lymphoma (NHL).
- Diffuse large B-cell lymphoma (DLBCL) has a significant relapse rate (>30%) after front-line therapy, necessitating improved strategies.
- Maintenance therapy post-induction offers potential to prolong remission in DLBCL.
Purpose of the Study:
- To review the efficacy and safety of maintenance therapies in diffuse large B-cell lymphoma (DLBCL).
- To evaluate targeted agents and immunomodulators in the maintenance setting for DLBCL.
- To identify potential patient subgroups who may benefit from maintenance strategies.
Main Methods:
- Systematic literature search of PubMed and congress abstracts.
- Focus on phase II/III studies of maintenance therapy following front-line induction for DLBCL.
- Analysis of efficacy and safety data for various agents, including rituximab, enzastaurin, everolimus, and lenalidomide.
Main Results:
- Rituximab maintenance after R-CHOP did not improve efficacy in DLBCL.
- Enzastaurin and everolimus showed no maintenance benefit in phase III trials.
- Lenalidomide maintenance demonstrated positive outcomes in higher-risk DLBCL patients, improving progression-free survival (PFS) in relapsed, transplant-ineligible patients.
- The REMARC trial showed improved PFS with lenalidomide versus placebo in elderly DLBCL patients post-R-CHOP, without affecting overall survival.
Conclusions:
- Lenalidomide shows promise as a maintenance therapy in DLBCL, particularly for specific patient populations.
- Further research is crucial to define optimal patient selection based on subtypes, risk status, and molecular profiles.
- Careful consideration of study endpoints is necessary for future DLBCL maintenance therapy trials.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
580
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
580
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:27Cytotoxic T Cells-mediated Immune Response
7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K